Author of

• 12915

  +

  MO19 - Lung Cancer Immunobiology (ID 91)

  • Event: WCLC 2013
  • Type: Mini Oral Abstract Session
  • Track: Biology
  • Presentations: 1
  • Moderators:Y. Sekido, J. Minna
  • Coordinates: 10/30/2013, 10:30 - 12:00, Bayside 201 - 203, Level 2

  • 12926

    +

    MO19.11 - Clinicopathological and prognosis features of PD-L1 in NSCLC patients in Chinese population. (ID 1302)

    10:30 - 12:00  |  Author(s): F. Zhou
    • Abstract
    • Presentation
    • Slides

    Background
    Programmed Death Ligand-1 is a ligand for Programmed cell death protein 1 which is a key receptor regarding one of the immune checkpoints. PD-L1 expression in tumor is known to correlate with post-operative survival in different set of cancer patients. In the present study, we investigated PD-L1 expression of tumor cells in specimens acquired from non-small cell lung cancer patients and analyzed the correlation between the PD-L1 expression and clinicopathological characteristics and postoperative prognosis of 208 Non-Small Cell Lung Cancer patients.

    Methods
    PD-L1 expression in 208 specimens of NSCLC was assessed through an immunohistochemical process and inspected double-blinded.

    Results
    PD-L1 expression is associated with clinicopathological features (histology, P=0.047 and differentiation, P=0.023). No significant association observed between PD-L1 expression and post-operative prognosis. However, subgroup analysis of squamous carcinoma patients with positive PD-L1 protein expression showed a tendency of poor overall survival and disease-free survival compared with those with negative PD-L1 protein expression.

    Conclusion
    we have shown for the first time that PD-L1 expression is associated with clinicopathological features (histology and differentiation). In the subgroup analysis of squamous carcinoma patients, patients with positive PD-L1 expression showed a tendency to be associated with poorer survival compared with those with negative PD-L1 expression, which suggested that patients with squamous carcinoma might be the most benefit population in the anti-PD-1 immunotherapy.

    Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.